ASPHF (Ascentage Pharma Group International) Moat Score: 3/10 (As of Jun. 25, 2026)


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Moat Score?

Ascentage Pharma Group International ASPHF -3.51% 71 Moat Score is 3 as of Jun. 25, 2026. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,405 Biotechnology companies, Ascentage Pharma Group International ranks better than 75.52% on this metric.

Ascentage Pharma Group International has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Ascentage Pharma Group International has No Moat: Ascentage Pharma Group International operates in a competitive pharmaceutical industry with limited market share and lacks significant regulatory barriers or exclusive licenses. Its R&D capabilities are not yet sufficient to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ascentage Pharma Group International might have No Moat - Very weak/transient advantages.

Ascentage Pharma Group International  (OTCPK:ASPHF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ascentage Pharma Group International Moat Score Related Terms

ASPHF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Moat Score distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Moat Score falls into.


ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Ascentage Pharma Group International (ASPHF) has a Moat Score of 3 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ascentage Pharma Group International ranks #344 out of 1405 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Ascentage Pharma Group International's Moat Score too high?
Ascentage Pharma Group International's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Ascentage Pharma Group International's value of 3 is 50% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #344 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #344 out of 1405 companies for Moat Score. This places Ascentage Pharma Group International in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Ascentage Pharma Group International's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Moat Score is 3 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Moat Score: 3
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1405)

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value